Biogen Pharmachem Industries Valuation
Is 531752 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 531752 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 531752's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 531752's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 531752?
Other financial metrics that can be useful for relative valuation.
What is 531752's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹737.44m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 78.1x |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 531752's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 54x | ||
539545 Apoorva Leasing Finance and Investment | 23.3x | n/a | ₹635.0m |
511609 ISL Consulting | 23.8x | n/a | ₹724.6m |
531278 Elixir Capital | 8.3x | n/a | ₹481.2m |
526241 Amrapali Industries | 160.7x | n/a | ₹747.0m |
531752 Biogen Pharmachem Industries | 74.3x | n/a | ₹737.4m |
Price-To-Earnings vs Peers: 531752 is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the peer average (54x).
Price to Earnings Ratio vs Industry
How does 531752's PE Ratio compare vs other companies in the IN Capital Markets Industry?
Price-To-Earnings vs Industry: 531752 is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the Indian Capital Markets industry average (23.7x).
Price to Earnings Ratio vs Fair Ratio
What is 531752's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 74.3x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 531752's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.